美国34个妊娠登记与自发报告对暴露妊娠的捕获对比
该研究通过系统综述识别药物和生物制剂的妊娠登记,用标准化问卷收集厂商的登记入组与保留数据及全球自发报告接收情况,并结合索赔数据计算每10万活产的暴露率。结果显示,妊娠期使用率越高的产品,其登记入组数越高;使用率极低的产品登记入组少,且与全球自发报告接收量的差异最明显。
要点
- 34个产品妊娠登记入组中位数为36例,自发报告捕获中位数为450例。
- 使用率>20/10万活产的产品登记入组中位数490例,自发报告中位数1061例。
- 使用率<0.5/10万活产的产品登记入组中位数3例,自发报告中位数41例。
核心结论
- 妊娠期使用率较高的产品预测妊娠登记入组数较高。
- 妊娠期极少使用的产品登记入组低,且与全球自发报告接收量的差异最明显。
- 妊娠期使用率极低的产品可能需要结合全球药物警戒、妊娠登记和其他研究方法来实现充分监测。
研究设计与样本
- 通过系统综述识别药物和生物制剂的妊娠登记,厂商通过标准化问卷提供登记入组与保留及全球自发报告接收信息。
- 使用经过验证的活产妊娠算法,结合索赔数据计算每10万活产的暴露率。
主要发现
- 34个有妊娠登记的产品中,登记入组中位数(四分位距)为36例(5-258),自发报告捕获中位数为450例(89-1192)。
- 使用率>20/10万活产的产品登记入组中位数490例,自发报告捕获中位数1061例。
- 使用率0.5-20/10万活产的产品登记入组中位数36例,自发报告中位数541例;使用率<0.5/10万活产的产品登记入组中位数3例,自发报告中位数41例。
- 24个入组≥10例妊娠的登记中,妊娠结局(如活产、自然流产)捕获中位数为83.9%。
- 19个入组≥10例婴儿的登记中,达到方案规定随访的婴儿比例中位数:出生后至4周为89.9%,1-5个月为75.0%,≥6个月为57.1%。
临床怎么用
- 临床药师应了解妊娠登记和自发报告是评估妊娠期药物安全性的重要药物警戒工具。
- 对于妊娠期使用率极低的药物,需结合全球药物警戒、妊娠登记和其他研究方法进行监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Pregnancy registries and spontaneous reports are essential pharmacovigilance tools to evaluate drug safety during pregnancy. OBJECTIVES: The aim of this study was to evaluate postmarket capture of exposed pregnancies. METHODS: Pregnancy registries for drugs and biologics were identified in a systematic review. Through a standardized questionnaire, manufacturers provided information on (1) pregnancy registry enrollment and retention, and (2) worldwide receipt of spontaneous reports for exposed pregnancies. A validated algorithm for live-birth pregnancies allowed calculation of exposure rates per 100,000 live births using claims data. RESULTS: Among 34 products with a pregnancy registry, median (interquartile range) registry enrollment was 36 pregnancies (5-258) and median spontaneous report capture was 450 pregnancies (89-1192). Products used in >20/100,000 live births had a median registry enrollment of 490 pregnancies and median capture of 1061 spontaneously reported exposed pregnancies. Lower median registry enrollment and spontaneous report capture was observed for products used in 0.5-20/100,000 live births (36 from registries, 541 spontaneous reports) and <0.5/100,000 live births (3 from registries, 41 spontaneous reports). Among 24 registries enrolling ≥10 pregnancies, median capture of pregnancy outcomes (e.g. live birth, spontaneous abortion) was 83.9%. For 19 registries enrolling ≥10 infants, the median proportion of infants achieving protocol-specified follow-up was 89.9% for up to 4 weeks post-birth, 75.0% for 1-5 months, and 57.1% for ≥6 months. CONCLUSIONS: Relatively higher product utilization among pregnant women predicted greater pregnancy registry enrollment. For products rarely used during pregnancy, registry enrollment was low and differences in registry enrollment compared with worldwide spontaneous report receipt were most pronounced. Products with very low utilization levels during pregnancy may require a combination of worldwide pharmacovigilance, pregnancy registries, and additional study methods to achieve adequate surveillance.
引用
- Bird ST, Gelperin K, Taylor L, et al. Enrollment and Retention in 34 United States Pregnancy Registries Contrasted with the Manufacturer's Capture of Spontaneous Reports for Exposed Pregnancies. Drug Saf. 2018. PMID: 28840499. doi:10.1007/s40264-017-0591-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。